Abiraterone acetate
SIGMA/SML1527 - ≥98% (HPLC)
Synonym: CB 7598; 17-
CAS Number: 154229-18-2
Empirical Formula (Hill Notation): C26H33NO2
Molecular Weight: 391.55
MDL Number: MFCD00934213
Linear Formula: C26H33NO2
Product Type: Chemical
assay | ≥98% (HPLC) |
color | white to beige |
form | powder |
InChI | 1S/C26H33NO2/c1-17(28)29- |
InChI key | UVIQSJCZCSLXRZ-UBUQANBQSA |
Quality Level | 100 |
SMILES string | C[C@]12C(C[C@@H](OC(C)=O) |
solubility | DMSO: 5 mg/mL, clear |
storage temp. | −20°C |
Application: | Abiraterone acetate has been used to study its antitumor action in 3D micro-tumour platform. |
Biochem/physiol Actions: | Abiraterone acetate is a prodrug of abiraterone, which is a potent, selective, and orally bioavailable inhibitor of CYP17A1 (CYP450c17), an enzyme that catalyzes two key serial reactions (17α hydroxylase and 17,20 lyase) in androgen and estrogen biosynthesis resulting in the formation of DHEA and androstenedione, which may ultimately be metabolized into testosterone. CYP17 is the key enzyme for androgen biosynthesis in both the testes and adrenals, so its inhibition should stop the production of androgens in both places. Abiraterone acetate is used for the treatment of metastatic castration-resistant prostate cancer. Abiraterone acetate possesses significant antitumor activity in post-docetaxel patients with CRPC (castration-resistant prostate cancer). It is highly essential for androgen biosynthesis in the testes, adrenal glands, and prostate tissue. |
Packaging: | 5, 25 mg in glass bottle |
Symbol | GHS08 |
Signal word | Danger |
Hazard statements | H360 - H372 |
Precautionary statements | P201 - P308 + P313 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC) |
Storage Temp. | −20°C |
UNSPSC | 12352200 |